Quick Answer
KalVista Pharmaceuticals, Inc. reported Operating Income of -$188.00 million for fiscal year 2025.
KalVista Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$188.00M | -33.9% |
| 2024 | -$140.44M | -26.7% |
| 2023 | -$110.87M | -14.8% |
| 2022 | -$96.61M | -66.8% |
| 2021 | -$57.92M | -42.9% |
| 2020 | -$40.53M | -35.9% |
| 2019 | -$29.82M | -59.4% |
| 2018 | -$18.70M | +16.3% |
| 2017 | -$22.34M | -47.2% |
| 2016 | -$15.18M | +27.8% |
| 2015 | -$21.04M | -160.1% |
| 2015 | -$8.09M | +30.7% |
| 2014 | -$11.68M | -123.9% |
| 2013 | -$5.22M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$46.05M | -5.9% | +22.0% |
| July 31, 2025 | -$59.01M | -33.5% | -37.4% |
| January 31, 2025 | -$42.94M | -29.5% | +6.3% |
| October 31, 2024 | -$45.81M | -54.0% | -5.4% |
| September 30, 2024 | -$43.48M | — | +1.7% |
| July 31, 2024 | -$44.22M | -52.0% | -33.4% |
| January 31, 2024 | -$33.15M | -23.0% | -11.4% |
| October 31, 2023 | -$29.75M | -14.9% | -2.2% |
- KalVista Pharmaceuticals, Inc. showed a decrease of -33.9% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, KalVista Pharmaceuticals, Inc.’s operating income has declined by 3504.2% (from -$5.22 million to -$188.00 million).
- The most recent figure is from KalVista Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: